Home›Stocks›CBIO

CBIO — structural market context

Crescent Biopharma, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 15. Each line shows the earlier value, the later value and their dates.

Price

Close $12.48 (Oct 15) vs $12.58 (Oct 14): −0.79%.

Volume

0.50× its 20-session average (540K) on Oct 15.

Includes pre- and post-market trading.

Short interest

Short interest 4.8M shares (settlement Sep 30) vs 3.4M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 1–Sep 14, published Sep 30): 2 days with fails, largest 42 shares on Sep 1.

Previous file (settlements Aug 17–Aug 31, published Sep 16): 3 days with fails, largest 1K shares on Aug 31.

No new publication in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

CBIO short interest & days to cover

SHARES SHORT
4.8M
% OF FLOAT
—
DAYS TO COVER
6.8
CHANGE VS PRIOR
+40.2%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (16d ago)

CBIO fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-24 · 22d2K$14.19
2026-09-02 · 44d42$17.93
2026-09-01 · 45d42$16.6

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

CBIO insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 9 sales

InsiderTypeSharesValueFiled
Lynch Ryan · officer: See RemarksSell (S)240$4K2026-09-18
Pinkas Jan · officer: Chief Scientific OfficerSell (S)658$12K2026-09-18
Im Ellie Eunkyung · officer: Chief Medical OfficerSell (S)623$11K2026-09-18
Scalzo Richard William · officer: Chief Financial OfficerSell (S)568$10K2026-09-18
Bispham Barbara Harlin · officer: See RemarksSell (S)620$11K2026-09-18

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

CBIO analyst ratings

FirmActionRatingPublished
H.C. WainwrightupgradeBuy (from Neutral)2026-10-06
H.C. Wainwrightprice_target—2026-10-06

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

Are insiders buying CBIO?
In the last 12 months of SEC Form 4 filings, CBIO recorded 0 insider purchases and 9 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about CBIO?
The most recent action: H.C. Wainwright upgrade to Buy on 2026-10-06. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell CBIO?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with C

CLF · Cleveland-Cliffs Inc.CAI · Caris Life Sciences, Inc. CommCASY · Casey's General Stores, Inc. CCATX · Perspective Therapeutics, Inc.CBLL · CeriBell, Inc.CHPT · ChargePoint Holdings, Inc.All C →

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.